Tesamorelin

Multi-Buy Savings — Add 2+ products to save 10% automatically. Add 3+ to save 15%. Applied at checkout.

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), comprising the full 44-amino acid sequence of GHRH with a trans-3-hexenoic acid moiety conjugated to the N-terminus for enhanced metabolic stability. This modification extends its plasma half-life relative to native GHRH while preserving high-affinity binding to the GHRH receptor (GHRH-R).

Tesamorelin is a clinically validated compound (FDA-approved as Egrifta for HIV-associated lipodystrophy), providing an extensive pharmacological and pharmacokinetic dataset for research context. Preclinical research examines its role in pulsatile GH secretion, IGF-1 pathway modulation, lipid metabolism, and neuroendocrine function. Its high receptor selectivity makes it a valuable tool for GHRH-R pathway investigation.

CAS: 218949-48-5  ·  MW: ~5135.9 g/mol  ·  Purity: ≥99% HPLC  ·  Format: Lyophilised powder  ·  Storage: −20 °C

Research Areas: GHRH-R pharmacology · Pulsatile GH secretion · IGF-1 signalling · Lipid metabolism · Lipodystrophy models · Neuroendocrine function

Research Literature:
• PubMed: Tesamorelin research literature →

Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.